Back to CME
CME Group: Valuation, Volume and Risks
$CMENEUTRALFinancial Services

CME Group: Valuation, Volume and Risks

CME Group reported a quarterly earnings beat and set a new volume record in Lean Hog futures and options, while revenue and earnings growth remain positive in the available data. Its share price is close to the analyst mean target, leaving valuation, trading activity and macroeconomic conditions central to the outlook.

November 14, 202610 min read
Current Price
$317.97
+0.78%
Analyst Rating
Buy
Price Target
$317.91
-0.0% upside
P/E Ratio
25.94

Executive Summary

Investment Thesis: CME Group operates a leading derivatives marketplace whose trading volumes can benefit from uncertainty in rates, commodities and other asset classes. Available financial data point to revenue growth of 13% and earnings growth of 16.1%, alongside a recent quarterly EPS beat and a 3.55% dividend yield. However, a 25.94 trailing P/E and analyst mean target near the current price suggest that much of the company’s quality is reflected in its valuation. The overall picture is balanced rather than one-sided.

Current Price: $317.97 as of Friday, November 13 | Key Metric: Analyst mean target $317.91 | Stance: NEUTRAL

Company Overview

CME Group operates a global derivatives marketplace where customers trade futures and options, as well as related products, to manage financial and commodity price risk. Its markets cover interest rates, equity indexes, foreign exchange, energy, metals and agricultural products. CME earns revenue from transactions and clearing, market data, and other services.

Key Products & Competitive Position

  • Core Business: Electronic and open-outcry derivatives trading, clearing and market data services for institutional and other market participants.
  • Key Products: Interest-rate futures, equity-index contracts, foreign-exchange futures and options, energy and metals contracts, and agricultural products such as Lean Hog futures and options.
  • Competitive Moat: Deep liquidity, established benchmark contracts, clearing infrastructure and the network effect of buyers and sellers meeting in the same markets. These features can make it difficult for a new venue to attract sufficient activity.

Recent Developments

On November 11, CME announced a new daily volume record of 209,363 contracts in Lean Hog futures and options. The record is a useful sign of product-specific activity, though a single contract’s volume does not by itself establish a durable change in company-wide earnings. Separately, the supplied financial snapshot reports 13% revenue growth and 16.1% earnings growth. A number of analysts raised price targets after the October 21 earnings release while leaving their ratings unchanged.

Financial Snapshot

Market Cap$113.81B
P/E Ratio25.94
52-Week Range$218.31 - $329.16
Dividend Yield3.55%
EPS (TTM)$12.29
ROE16.24%

Revenue & Earnings Trends

The supplied financial data list total revenue of approximately $6.96 billion, revenue growth of 13%, earnings growth of 16.1%, and free cash flow of roughly $3.05 billion. These figures suggest that earnings have grown faster than revenue in the reported snapshot, but the data provided do not include a full quarterly or annual comparison series. Treat the growth rates as indicators from the available data, not as a guarantee that the pace will persist. The latest supplied quarter, reported October 21, showed EPS of $3.02 against a $2.99 estimate, a modest beat of about 1%.

Balance Sheet Highlights

CME reported about $2.33 billion in cash and $3.85 billion in total debt, with a debt-to-equity ratio of 14.51%. Its current ratio is 1.02, close to parity, while the reported quick ratio is only 0.02. For an exchange and clearing business, these liquidity ratios need context: customer and clearing-related balances can make simple comparisons with industrial companies less informative. The figures still warrant monitoring alongside cash generation, debt maturities and obligations tied to clearing operations.

Valuation Analysis

Current Valuation Metrics

Forward P/E24.0Industry comparison not supplied
PEG Ratio4.35Growth-adjusted, based on supplied data
EV/EBITDA23.34Historical comparison not supplied
P/S Ratio16.58Peer comparison not supplied

Historical Comparison

A reliable five-year average for CME’s valuation was not included in the supplied information, so a numerical comparison with its own history would be speculative. The two-year price data show an average closing price of $262.36 and a reported total return of 54.44%, but those figures describe share performance, not the valuation multiple paid at different points in time. The current trailing P/E of 25.94 and forward P/E near 24 indicate that the market assigns a meaningful premium to CME’s earnings and business resilience.

Fair Value Estimate

The analyst mean target supplied is $317.91, effectively at the Friday, November 13 close of $317.97. The median target is higher at $330, while the range from $227 to $367 is wide. Those targets are not a substitute for an independent valuation. With no complete forecast model, discount rate or five-year multiple history provided, a precise DCF estimate cannot be responsibly calculated. The central valuation evidence is therefore mixed: durable infrastructure and reported growth support a premium, while a PEG ratio of 4.35 and limited average-target upside leave little evidence of a clear valuation discount.

Competitive Landscape

Market Position

Market Share: Not provided in the supplied data | Ranking: Leading global derivatives marketplace

Key Competitors

Intercontinental Exchange (ICE)Intercontinental Exchange operates futures and options markets, clearing services and exchanges including ICE Futures.
Cboe Global Markets (CBOE)Cboe Global Markets competes in listed options, volatility products, equities and derivatives trading.
Nasdaq (NDAQ)Nasdaq operates exchange and market technology businesses, including markets for listed options and other financial products.

Competitive Advantages

  • Liquidity and network effects: High participation can make CME’s established contracts more useful to customers and harder for competing venues to replicate.
  • Clearing infrastructure: Central clearing and risk management are important parts of the value proposition for counterparties seeking to manage exposures.
  • Product breadth: Coverage across rates, equity indexes, currencies and commodities gives customers multiple ways to manage risk within one marketplace.

Earnings Track Record

Last 4 Quarters: 1 documented beat / 0 documented misses, results for three quarters were not supplied

Recent Earnings History

Q3 2026$3.02 vs $2.99 estBEAT
Q2 2026Not suppliedN/A
Q1 2026Not suppliedN/A
Q4 2025Not suppliedN/A

Guidance Trend

No full-year management guidance or revision history was included in the supplied data. The next listed report is expected February 3, 2027, with consensus EPS of $3.01. That estimate is a market expectation rather than company guidance. Investors can compare the eventual result with the estimate and listen for commentary on trading volumes, revenue per contract, expenses and demand across asset classes.

Analyst Sentiment

Consensus Rating: Buy, according to the supplied analyst consensus

Strong Buy: 5 Buy: 4 Hold: 6 Sell: 1 Strong Sell: 1

Price Targets

  • Low: $227
  • Mean: $317.91 (approximately 0.0% downside, effectively flat)
  • High: $367

Recent Analyst Actions

Following the October 21 earnings report, UBS raised its target to $310 from $270 while maintaining Neutral; Morgan Stanley raised its target to $359 from $337 and maintained Overweight; Barclays moved its target to $321 from $281 while maintaining Equal-Weight; and Wells Fargo raised its target to $333 from $315 while maintaining Overweight. The supplied datasets differ slightly on analyst coverage: one lists 17 analysts and a $317.91 mean target, while the Yahoo Finance extract lists 16 opinions and a $317.06 mean. The differences are small for the mean, but a reminder that consensus counts and targets vary by data provider.

Recent News & Catalysts

Key Developments

  • Lean Hog volume record: CME announced that Lean Hog futures and options reached a daily record of 209,363 contracts on November 11. Sustained activity would be more meaningful than a single-day record, so follow-through in subsequent volume data matters.
  • October earnings beat: On October 21, CME reported EPS of $3.02 against the $2.99 estimate. Analysts subsequently raised several price targets, though the cited firms kept their existing ratings.
  • Rates and market uncertainty: A November 10 news item described increased rate trading in October and discussion of a possible Federal Reserve rate hike. Volatility and shifting expectations can support hedging demand, but activity levels are uncertain and can change as market conditions evolve.

Upcoming Catalysts

Next Earnings: February 3, 2027, expected | Key Events: Quarterly trading volumes, the December 11 ex-dividend date for the reported $1.30 cash dividend, Federal Reserve rate decisions, and activity in agricultural and other commodity contracts

Technical Outlook

Current Price: $317.97 as of Friday, November 13, versus 52-Week High: $329.16 (3.4% below the high)

Trend Analysis

U.S. equity markets were closed on Saturday, November 14, and the price reference here is the supplied Friday close. The provided session data show a $2.47, or 0.78%, gain from the prior close of $315.50, with a reported range of $316.31 to $320.26. CME is near the upper end of its 52-week range, about 45.6% above the $218.31 low. The two-year data show an average close of $262.36 and a 54.44% total return, but moving averages and trading volume for technical confirmation were not supplied.

Key Levels

  • Resistance: $320.26, the supplied Friday session high; $329.16, the 52-week high
  • Support: $316.31, the supplied Friday session low; $315.50, the previous close. These are near-term reference points, not confirmed technical support levels.

Bull vs Bear Case

Bull Case

  • Volume and uncertainty: Market uncertainty and changing rate expectations can increase demand for hedging and trading across CME’s products.
  • Growth and cash generation: The supplied snapshot reports 13% revenue growth, 16.1% earnings growth and $3.05 billion in free cash flow, alongside a recent EPS beat.
  • Market infrastructure: Liquidity, clearing capabilities and established contracts can support resilience and the 3.55% indicated dividend yield.

Bull Target: $367, the highest supplied analyst target, about 15.4% above the Friday close. This is an analyst estimate, not a forecast.

Bear Case

  • Valuation sensitivity: A trailing P/E of 25.94 and PEG ratio of 4.35 leave the share price sensitive to slower growth or a lower market multiple.
  • Activity risk: Trading volumes vary with volatility, customer hedging needs and market conditions. A single product record may not translate into sustained company-wide growth.
  • Target dispersion: The low analyst target of $227 is far below the current price, and the mean target is effectively flat, highlighting downside scenarios as well as uncertainty.

Bear Target: $227, the lowest supplied analyst target, about 28.6% below the Friday close. This is an analyst estimate, not a forecast.

Risks to Consider

  • Valuation Risk: CME trades at a premium valuation, and a slowdown in earnings growth or a change in market expectations could put pressure on valuation multiples.
  • Competitive Risk: ICE, Cboe and other venues compete for products, customers and trading activity. CME’s network effects are meaningful, but not a guarantee against changing customer preferences or market structure.
  • Macro Risk: Interest rates, geopolitical developments and commodity prices influence trading and hedging demand. Lower uncertainty can reduce activity in some products, while sharp market moves can also increase operational and risk-management demands.
  • Execution Risk: CME must maintain reliable technology, clearing operations, cybersecurity and regulatory compliance. Disruptions or control failures could undermine confidence in its markets.

Bottom Line

Investment Verdict: NEUTRAL

CME combines a durable marketplace position, positive growth in the supplied financial snapshot and a recent earnings beat with a valuation that leaves limited room between the share price and the analyst mean target. The central question is whether trading activity and earnings can continue to support the current premium; the available data support both an operating-strength case and a valuation-risk case. This analysis is informational and is not investment advice.

Action Items for Investors

  • Long-term investors: Assess CME’s trading-volume resilience, cash generation and dividend history against its current valuation, while recognizing that the supplied growth rates may not persist.
  • Short-term traders: Treat the Friday close, session range and 52-week high as reference points rather than signals on their own. U.S. markets are closed for the weekend and next open Monday, November 16.
  • Risk management: Consider the wide analyst target range, macro sensitivity and the difference between reported company results and third-party estimates when evaluating exposure.

What to Watch This Week

  • Whether CME releases follow-up volume data after the Lean Hog daily record.
  • Market expectations for Federal Reserve policy and the resulting activity in rate futures.
  • Trading behavior when U.S. markets reopen Monday, November 16, alongside the stock’s proximity to its 52-week high.

Share this report

Share this article

Spread the word on social media

Think CME will outperform? Prove it.

Free practice contests — earn Alpha Coins
Enter a Contest

Disclaimer: StockAlpha.ai content is for informational and educational purposes only. It is not personalized investment advice. Sentiment ratings and market analysis reflect data-driven observations, not buy, sell, or hold recommendations. Always consult a qualified financial advisor before making investment decisions. Past performance does not guarantee future results.

Spotted something wrong? Report an error.